These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2468004)

  • 1. [Functions and structure of complement inactivators in membrane proteins. 2). Decay-accelerating factor].
    Sugita Y
    Nihon Rinsho; 1988 Sep; 46(9):1927-32. PubMed ID: 2468004
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    Nicholson-Weller A; Burge J; Fearon DT; Weller PF; Austen KF
    J Immunol; 1982 Jul; 129(1):184-9. PubMed ID: 6211481
    [No Abstract]   [Full Text] [Related]  

  • 3. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
    Kameyoshi Y; Matsushita M; Okada H
    Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
    Fujita T; Shinkai Y; Inoue T; Tamura N
    Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
    Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
    J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional forms of human decay-accelerating factor (DAF).
    Seya T; Farries T; Nickells M; Atkinson JP
    J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    Schönermark S; Rauterberg EW; Shin ML; Löke S; Roelcke D; Hänsch GM
    J Immunol; 1986 Mar; 136(5):1772-6. PubMed ID: 2419413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor.
    Norris KA; Bradt B; Cooper NR; So M
    J Immunol; 1991 Oct; 147(7):2240-7. PubMed ID: 1717552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Functions and structure of complement inactivators in plasma. 2). I factor].
    Hirose S; Kaneko I
    Nihon Rinsho; 1988 Sep; 46(9):1904-9. PubMed ID: 2977202
    [No Abstract]   [Full Text] [Related]  

  • 12. Isolation of decay-accelerating factor (DAF) from rabbit erythrocyte membranes.
    Sugita Y; Uzawa M; Tomita M
    J Immunol Methods; 1987 Nov; 104(1-2):123-30. PubMed ID: 2445823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
    Schultz DR
    Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and molecular genetics of complement proteins. An update.
    Volanakis JE
    Year Immunol; 1986; 2():164-76. PubMed ID: 3554821
    [No Abstract]   [Full Text] [Related]  

  • 17. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
    Kinoshita T; Medof ME; Nussenzweig V
    J Immunol; 1986 May; 136(9):3390-5. PubMed ID: 2420889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complement regulatory membrane factors in experimental animal models].
    Okada N
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):631-3. PubMed ID: 8963768
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.